Category: 2020

Top 20 Immunology Companies Based on 2020 Immunology Segment Revenue

August 12, 2021 Auto Bot 0

Immunology deals with physiological functioning of the immune system in states of both health and disease as well as malfunctions of the immune system in […]

Top 20 BioPharma Companies based on 2020 Total Revenue

April 8, 2021 Auto Bot 0

Despite having the global pandemic, the biopharma companies were involved in multiple M&A, licensing deals. The major focus of the year remains the production and […]

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

March 11, 2021 Auto Bot 0

Breakthrough Therapy (BT) Designation is an expedited review program introduced in Section 902 of the Food and Drug Safety and Innovation Act of 2012 The […]

Top 20 Biopharma Deal Terminations of 2020 Based on Total Deal Value

February 11, 2021 Auto Bot 0

The biopharma industry saw numerous deal terminations in 2020. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were among the most common […]

What Were the Biggest Advances in Life Sciences in 2020?

February 8, 2021 Auto Bot 0

As we settle into a new year, it’s always good to take a moment to consider what was accomplished in the previous one. That’s why […]

Insights+ Key Biosimilars Events of December 2020

January 28, 2021 Auto Bot 0

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective […]

Top 20 Life Sciences Deals of 2020 by Total Deal Value

January 22, 2021 Auto Bot 0

Life sciences companies are gearing up to enter new markets as they look to secure their positions after a spate of M&A, licensing, and research […]

Insights+: The US FDA New Drug Approvals in December 2020

January 21, 2021 Auto Bot 0

The US FDA has approved 7 NDAs and 2 BLA in Nov 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug […]

Telehealth, online pharmacy key focus for UnitedHealth, leaders say

January 21, 2021 Auto Bot 0

UnitedHealth’s 2020 revenue jumped by $15 billion from the year before. As the payer gears up for 2021, leaders except to see demand for telehealth […]

PharmaShots’ Key Highlights of Fourth Quarter 2020

January 14, 2021 Auto Bot 0

The fourth quarter of 2020 contains multiple initiations of clinical trials, big approvals, and numerous deals. COVID-19 related news remains at the peak in this […]

PharmaShots’ Most Read News of 2020

December 31, 2020 Auto Bot 0

“Lockdown’ declared Collins Dictionary word of the year. The year 2020, well known as COVID-19 year has been a busy year for global pharma and […]

Insights+: The US FDA New Drug Approvals in November 2020

December 17, 2020 Auto Bot 0

The US FDA has approved 5 NDAs and 1 BLA in Nov 2020, leading to treatments for patients and advances in the health care industry. […]

Nektar Therapeutics Presents Preclinical Data of NKTR-255 in P-Ib/II Study at ASH 2020

December 8, 2020 Auto Bot 0

Shots: Nektar presents two nonclinical data presentations for NKTR-255 at the 62nd ASH Annual Meeting, which include an oral presentation of translational research studies conducted […]

Insights+ Key Biosimilars Events of November 2020

December 3, 2020 Auto Bot 0

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective […]

ViewPoints Interview: FibroGen’s Peony Yu Shares Insight on Roxadustat

December 3, 2020 Auto Bot 0

In a recent interview with PharmaShots, Peony Yu, Chief Medical Officer of FibroGen shared her insights and highlights on data of Roxadustat Shots: FibroGen presented […]

Celltrion Reports Results of CT-P59 in P-I Study for COVID-19

November 9, 2020 Auto Bot 0

Shots: The P-I clinical trial involves assessing CT-P59 (20/40/80 mg/kg) vs PBO in 18 patients with mild symptoms of SARS-COV-2 infection who were randomized into […]

Eisai Reports Results of Lenvima (lenvatinib) + Everolimus in P-II 218 Study for Advanced Renal Cell Carcinoma

November 9, 2020 Auto Bot 0

Shots: The P-II 218 study involves assessing Lenvima (14mg, qd) + everolimus (5mg, qd) vs Lenvima (18mg, qd) + everolimus (5mg qd) in patients with […]

Innovent and Lilly Report Results of Tyvyt (sintilimab) in Seven Clinical Studies to be Presented at the ESMO ASIA Congress 2020

November 5, 2020 Auto Bot 0

Shots: The 7 studies include one Proffered Paper Oral Presentation & 6 e-posters, covering indications including lung cancer, liver cancer, gastric cancer, & esophageal cancer […]